High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The need for a standardized treatment protocol for multidrug resistant tuberculosis (MDR-TB)
in resource-limited countries is being increasingly recognized. This single center, double
blind, randomized controlled trial was designed to compare the time required for sputum
culture conversion and extent of radiological improvement in cases of MDR pulmonary
tuberculosis when isoniazid was included (both at a regular dose and at a high dose) as an
adjuvant to the standardized second line of treatment. The study was designed to test the
hypothesis that inclusion of high-dose isoniazid will enhance the effectiveness of the second
line of treatment in cases of MDR-TB without significantly increasing the toxicity.